Last reviewed · How we verify
Enalapril 5mg
At a glance
| Generic name | Enalapril 5mg |
|---|---|
| Sponsor | Vanderbilt University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Hydroxychloroquine in Patients With X-linked Alport Syndrome in China (CHXLAS) (PHASE2)
- Nifedipine and Enalapril vs Nifedipine and Labetalol for the Treatment of Postpartum Hypertension Study (NA)
- Study of Efficacy and Safety of LCZ696 in Japanese Patients With Chronic Heart Failure and Reduced Ejection Fraction (PHASE3)
- NT-proBNP Selected Prevention of Cardiac Events in Diabetic Patients (PHASE4)
- Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia (PHASE2)
- Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction (PHASE4)
- The Use of ACE Inhibitors in the Early Renal Post-transplant Period (PHASE1)
- Comparing ARNI With ACE Inhibitor on Endothelial Function (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enalapril 5mg CI brief — competitive landscape report
- Enalapril 5mg updates RSS · CI watch RSS
- Vanderbilt University portfolio CI